Transplantation Infection Clinical Trial
Official title:
Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome
Stenotrophomonas maltophilia is a multi-resistant Gram-negative bacillus and is an opportunistic pathogen. Stenotrophomonas maltophilia infections are associated with a significant morbidity and mortality, particularly in immunocompromised patients. The mortality of infections (bacteremia, pneumonia) related to Stenotrophomonas maltophilia is variable and is estimated between 21 and 69%. Stenotrophomonas maltophilia pneumopathies have been mainly described in patients hospitalized in intensive care and benefiting from mechanical ventilation. The existence of immunosuppression seems to be a risk factor for the transition from Stenotrophomonas maltophilia pulmonary colonization to Stenotrophomonas maltophilia pulmonary infection. The reference treatment for Stenotrophomonas maltophilia-associated pneumonia is the combination of trimethoprim and sulfamthoxazole, a molecule that lung transplant patients routinely receive as a preventive treatment for Pneumocysitis jirovecii infection. There is no consensus on the value of routine dual-antibiotic therapy, and it varies from one center to another and from one country to another. The main objective is to compare the clinical-microbiological evolution of lung transplant patients treated for Stenotrophomonas maltophilia pneumopathy according to the prescription of a mono- or bi-antibiotherapy. The secondary objective is to evaluate the resistance rate of Stenotrophomonas maltophilia strains isolated from respiratory samples according to the anti-pneumocystis prophylactic molecule received by the patient.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05047406 -
Bacillus Clausii in Liver Transplantation
|
Phase 2 | |
| Completed |
NCT02463214 -
Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients
|
N/A | |
| Recruiting |
NCT05198570 -
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
|
||
| Completed |
NCT01808456 -
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
|
Phase 4 | |
| Suspended |
NCT01301118 -
Graft Take and Microbiology in Burns
|
N/A | |
| Completed |
NCT00610961 -
Induction Related BK Viremia in Renal Transplant Patients
|
Phase 4 | |
| Recruiting |
NCT05215327 -
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
|
Phase 2 | |
| Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02811835 -
TransplantLines Food and Nutrition Biobank and Cohort Study (TxL-FN)
|
N/A | |
| Completed |
NCT01471444 -
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
| Enrolling by invitation |
NCT01349738 -
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants
|
N/A | |
| Terminated |
NCT00473824 -
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
|
Phase 2 | |
| Completed |
NCT00177801 -
Organ Transplant Infection Prevention and Detection Project
|
Phase 4 | |
| Completed |
NCT01276457 -
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
|
Phase 3 | |
| Completed |
NCT02328963 -
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
|
Phase 4 | |
| Recruiting |
NCT04320303 -
CMV Infection and Immune Intervention After Transplantation
|
N/A | |
| Active, not recruiting |
NCT01295645 -
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
|
Phase 2 | |
| Completed |
NCT02329808 -
Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
|
||
| Completed |
NCT01471067 -
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04579471 -
Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
|